We are pleased to announce that Anne Chevrel (Head of Discovery & Technology) and Cécile Durand (Business Development) will represent Mabqi at the Antibody Engineering & Therapeutics Europe congress, taking place from May 27 to 29, 2026, at the Congress Center in Basel, Switzerland.
As one of Europe’s premier events dedicated to antibody discovery, engineering, and therapeutic development, AET Europe brings together leading scientists, innovators, and industry experts from across the field.
On May 28 at 3:25 PM, Mabqi will deliver a talk entitled:
“Preclinical Progress of a Novel Tumor-Specific Anti-CD30 ADC Designed to Bypass the Antigen Sink Effect”.
During this presentation, attendees will gain insights into:
Cutting-edge approaches in tumor-selective antibody generation and characterization
This congress represents an exciting opportunity to share our scientific advances, engage with the antibody engineering community, and foster valuable collaborations with academic and industry partners.
We look forward to connecting with you and contributing to the future of therapeutic antibody and protein engineering in Basel.
